Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.69 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.68 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.68 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.68 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.64 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.62 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | RXRA | P19793 | 1/20 | 0.57 |
| ▸ | RXRB | P28702 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103047 | 0.88 | MAOB (0.65) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL5078379 | 0.88 | MAOB (0.65) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL169289 | 0.88 | MAOB (0.65) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| Hydrochloric Acid SCHEMBL9641061 | 0.86 | MAOB (0.63) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL13110201 | 0.86 | MAOB (0.63) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL22386732 | 0.86 | SMN1; SMN2 (0.69) | MAOBPARP10PLA2G4BALDH1A1HTT | |
| SCHEMBL18417685 | 0.86 | MAOB (0.51) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL10844954 | 0.85 | NR4A1 (0.70) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL6803381 | 0.85 | MAOB (0.61) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL3395533 | 0.84 | NR4A1 (0.68) | MAOBNR4A1NR4A2NR4A3PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947271-B2 | Antibacterial agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2021-03-16 | — | — | US | disclosed |
| US-20170204138-A1 | ANTIBACTERIAL AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-20 | — | — | US | disclosed |
| US-20170204138-A1 | ANTIBACTERIAL AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-20 | — | — | US | disclosed |
| CN-102316733-B | Heterocyclic compounds and methods of use | GENENTECH INC | 2014-01-01 | — | — | CN | disclosed |
| US-7737287-B2 | Anomeric derivatives of monosaccharides | ALCHEMIA LIMITED (AU) | 2010-06-15 | — | — | US | disclosed |
| US-20100087661-A1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | ZENTIVA K.S. (CZ) | 2010-04-08 | — | — | US | disclosed |
| EP-1159267-B1 | N-SUBSTITUTED INDOLINES AS ESTROGENIC AGENTS | WYETH CORP (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6358943-B1 | TREATMENT OF OSTEOPOROSIS, BENIGN PROSTATIC HYPERPLASIA, BREAST AND/OR ENDOMETRIAL CANCER | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-19 | — | — | US | disclosed |
| EP-1159267-A1 | N-SUBSTITUTED INDOLINES AS ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000051982-A1 | N-SUBSTITUTED INDOLINES AS ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087661-A1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | CYP19A1, CYP17A1, SHBG | MAOB 85/4885NR4A1 661/4885NR4A2 924/4885 |
| US-20170204138-A1 | ANTIBACTERIAL AGENTS | VNN1, ASNS, AAAS | MAOB 3041/4885NR4A1 3210/4885NR4A2 4212/4885 |
| US-10947271-B2 | Antibacterial agents | VNN1, ASNS, AAAS | MAOB 3041/4885NR4A1 3210/4885NR4A2 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.